Talarico Laura B, Castilla Viviana, Ramirez Javier A, Galagovsky Lydia R, Wachsman Mónica B
Laboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Argentina.
Chemotherapy. 2006;52(1):38-42. doi: 10.1159/000090242. Epub 2005 Dec 9.
The replication of herpes simplex virus (HSV) type 1 in Vero cells is inhibited in the presence of (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one (6b), a synthetic brassinosteroid derivative. Since a late step of virus multiplication is hindered by 6b, we performed studies of drug-drug combination with acyclovir (ACV) and foscarnet (FOS). It was determined that 6b would act synergistically with low concentrations of ACV and moderate concentrations of FOS against HSV. The best drug combination tested in this study resulted in an increase of 29.3 and 47.2% in antiviral activity for ACV (0.036 microM) and FOS (37.5 microM) in the presence of 14.8 and 6.9 microM of 6b, respectively.
在合成油菜素内酯衍生物（22S,23S）-3β-溴-5α,22,23-三羟基豆甾-6-酮（6b）存在的情况下，单纯疱疹病毒1型（HSV）在非洲绿猴肾细胞（Vero细胞）中的复制受到抑制。由于病毒增殖的后期步骤受到6b的阻碍，我们开展了6b与阿昔洛韦（ACV）和膦甲酸钠（FOS）联合用药的研究。结果表明，6b与低浓度的ACV和中等浓度的FOS联合使用时，对HSV具有协同作用。本研究中测试的最佳药物组合，在分别存在14.8 μM和6.9 μM的6b时，ACV（0.036 μM）和FOS（37.5 μM）的抗病毒活性分别提高了29.3%和47.2%。
Zotero 插件